PT-141 (Bremelanotide) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

PT-141 (Bremelanotide)

Also known as: Bremelanotide, Vyleesi, PT-141

Melanocortin receptor agonist (synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone [α-MSH])

FDA-approvedLast updated: October 31, 2026Based on 25 peer-reviewed studies

What it is

PT-141 (bremelanotide) is the active ingredient in Vyleesi, FDA-approved for treating low sexual desire in premenopausal women. It works through brain pathways that regulate sexual arousal, unlike other treatments that act on blood flow. Prescription-only for that indication; also used off-label by men for erectile dysfunction.

The scientific side

Bremelanotide is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a non-selective melanocortin receptor (MCR) agonist, with melanocortin type 4 receptor (MC4R) considered the most relevant subtype at therapeutic doses (PMIDs: 33455598, 31429064). MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus, an area important for female sexual function. Animal studies suggest bremelanotide may activate presynaptic MC4Rs on neurons in the mPOA, leading to increased release of dopamine, an excitatory neurotransmitter associated with increased sexual desire. Bremelanotide also activates melanocortin receptors 3 and 4 in glioblastoma cell lines, reducing survivin expression and inducing cell death in vitro. MC4R plays a central role in appetite regulation; agonist activity at this receptor promotes satiety. High-resolution structural studies have confirmed bremelanotide's binding mode at full-length MC4R in complex with heterotrimeric Gs protein. Earlier literature noted bremelanotide was also studied via intranasal route and proposed to act in the CNS to promote erections in preclinical models, and to stimulate behaviors facilitating sexual activity in both male and female models (PMIDs: 18552829, 17983889).

Class: Melanocortin receptor agonist (synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone [α-MSH])

FDA-approvedSexualMelanocortin receptor agonist (MC1R/MC4R)

At a glance

What it isBremelanotide, a synthetic peptide related to alpha-MSH that activates melanocortin receptors in the brain and skin.
Approved forLow sexual desire that causes distress (hypoactive sexual desire disorder, HSDD) in premenopausal women. Sold as Vyleesi.
Route1.75 mg injected under the skin of the abdomen or thigh with an autoinjector.
Dosing cadenceOn demand: at least 45 minutes before sexual activity, no more than once in 24 hours and no more than 8 times a month. Not taken on a schedule or cycle.
Evidence strengthFDA approved, based on two 24-week phase 3 trials in 1,267 women and a 52-week extension.
Key risksA temporary rise in blood pressure after each dose, nausea in 40% of users, and skin darkening with frequent use.

What is PT-141?

PT-141 is the research name for bremelanotide, a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Since 2019 it has been sold in the US as Vyleesi, a prefilled autoinjector, by prescription.

It is related to Melanotan II, but it is approved and dosed very differently. Outside the label, PT-141 is also sold as a research peptide and used by men for sexual function.

Sources: [1] [2]

How does it work?

Bremelanotide activates several melanocortin receptors, in this order of potency: MC1R, MC4R, MC3R, MC5R and MC2R. The label says that "at therapeutic dose levels, binding to MC1R and MC4R is most relevant." MC4R is found in many brain areas; MC1R sits on pigment cells, which is why repeated use can darken skin.

The label is candid that "the mechanism by which VYLEESI improves HSDD in women is unknown." It works on desire in the brain, not on blood flow like erectile dysfunction drugs.

Pharmacokinetics

Half-lifeAbout 2.7 hours (label)
MetabolismBroken down by hydrolysis of its peptide bonds (label)
ClearanceAbout 65% of a radiolabeled dose recovered in urine and 23% in feces (label)
RouteSubcutaneous injection; peak level about 1 hour after the dose

Sources: [2]

Is it FDA-approved?

Yes. The FDA approved bremelanotide as Vyleesi on June 21, 2019. The label was last updated in October 2026.

Sources: [3] [4]

What is PT-141 prescribed for?

Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder: low sexual desire that causes marked distress or relationship difficulty and is not due to another medical or psychiatric condition, relationship problems, or a medication.

In the two phase 3 trials, women on bremelanotide had statistically significant increases in desire and reductions in distress compared with placebo. The label says to stop after 8 weeks if there is no improvement, and that it is "not indicated to enhance sexual performance."

FDA-approved use: Hypoactive sexual desire disorder (HSDD) in premenopausal women

Also studied for

  • Erectile response in men (intranasal, early 2000s; not approved)

Off-label use: Men use PT-141 for sexual function, but Vyleesi is "not indicated for the treatment of HSDD in postmenopausal women or in men." Early studies in men used a nasal spray at much higher doses.

Who should not use it

  • Uncontrolled hypertension
  • Known cardiovascular disease
  • Not recommended for people at high risk for cardiovascular disease

Sources: [2] [5]

Dosing and safety monitoring

Blood pressure

Each dose raises blood pressure by up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and usually back to baseline within 12 hours; heart rate drops by up to 5 beats per minute. The label asks prescribers to consider cardiovascular risk and "ensure blood pressure is well-controlled" before starting and periodically during treatment. If you take blood pressure medication or have any heart concerns, check your blood pressure before using it.

Dosing limits

1.75 mg at least 45 minutes before anticipated sexual activity. No more than one dose in 24 hours, because doses close together may add up their effect on blood pressure. More than 8 doses a month is not recommended: it raises the chance of skin darkening and the time each month that blood pressure is raised.

What to watch for

  • Skin darkening (focal hyperpigmentation): 1% of women taking up to 8 doses a month; 38% after 8 daily doses in a row in a separate study
  • Nausea: 40% of women in the phase 3 trials, the most common side effect
  • Slower stomach emptying, which can delay or reduce absorption of oral medicines taken at the same time

Avoid combining with

  • Oral naltrexone for alcohol or opioid dependence: Vyleesi may significantly lower naltrexone levels, and naltrexone failing can have severe consequences
  • Oral drugs that need a threshold level to work (for example antibiotics), because of slower stomach emptying

Sources: [2] [6]

Side effects

In the phase 3 trials, the most common side effects (more than 4% of women) were nausea, flushing, injection site reactions, headache and vomiting. Nausea led 8% of women to stop treatment; for most it improves by the second dose.

Each dose briefly raises blood pressure and lowers heart rate. Skin darkening (focal hyperpigmentation) on the face, gums or breasts can occur and did not always fade after stopping. In the 52-week extension, no new safety signals appeared.

Common

  • Nausea: 40.0% vs 1.3% on placebo
  • Flushing: 20.3% vs 0.3%
  • Injection site reactions: 13.2% vs 8.4%
  • Headache: 11.3% vs 1.9%
  • Vomiting: 4.8% vs 0.2%

Serious

  • Temporary blood pressure increase after each dose (up to 6/3 mmHg)
  • Focal hyperpigmentation that may not fade
  • One case of acute hepatitis in which a role for Vyleesi could not be excluded

FDA label, Table 1: adverse reactions in at least 2% of patients in the 24-week phase 3 trials (1,247 women).

Sources: [2] [7]

Rare events and case reports

Acute hepatitis case

In the open-label extension of one trial, a woman who had taken 10 doses over a year developed acute hepatitis, with liver enzymes over 40 times the upper limit of normal and bilirubin 6 times normal. Her liver tests returned to normal 4 months after stopping. No other cause was found, so the label says Vyleesi's role "could not definitively be excluded"; there was no wider liver signal across the trials. If you develop abdominal pain, yellowing skin or eyes, dark urine or unusual tiredness while using it, stop and ask a clinician for liver tests (ALT, AST).

Sources: [2]

FAQ

How soon before sexual activity should PT-141 be taken?

At least 45 minutes before. The label says the best timing has not been fully worked out, so people adjust based on how long it lasts for them and on side effects like nausea.

Sources: [2]

Can men use PT-141?

Not as an approved use: the label says Vyleesi is not indicated in men. Early studies in men used a nasal spray, and erections increased at doses above 7 mg.

Sources: [2] [8]

What are the blood pressure risks?

Each dose raises blood pressure up to about 6/3 mmHg for several hours. It is contraindicated with uncontrolled high blood pressure or known heart disease, and you should not take more than one dose in 24 hours.

Sources: [2] [6]

What does hyperpigmentation mean here?

Darker patches of skin, gums or breasts. It affected 1% of women using up to 8 doses a month but 38% after 8 daily doses in a row, and it did not always fade after stopping.

Sources: [2]

Why is naltrexone a problem?

Vyleesi can sharply lower the level of oral naltrexone, so naltrexone taken for alcohol or opioid dependence might stop working. The label says to avoid the combination.

Sources: [2]

What happened in the hepatitis case?

One woman in the long-term extension developed acute hepatitis after 10 doses over a year and recovered after stopping. No other cause was found, so a link could not be ruled out. Stop and get liver tests if you notice abdominal pain, jaundice or dark urine.

Sources: [2]

How often can PT-141 be used?

No more than once in 24 hours and no more than 8 times a month. Stop after 8 weeks if it has not helped.

Sources: [2]

Can it be used while breastfeeding?

The October 2026 label says bremelanotide passes into breast milk "in clinically insignificant amounts" (about 0.13% of the mother's dose). Use during pregnancy is not recommended.

Sources: [2] [4]

Is PT-141 banned in sport?

It is not named on the 2026 WADA Prohibited List. Athletes should still check with their anti-doping organization.

Sources: [9]

Citations

  1. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003. PMID 12851303
  2. VYLEESI (bremelanotide injection) prescribing information, NDA 210557, revised October 2026 (S-005). accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf
  3. FDA approval letter for Vyleesi (NDA 210557), June 21, 2019. accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
  4. FDA supplement approval letter, NDA 210557 S-005 (Section 8 update), October 22, 2026. accessdata.fda.gov/drugsatfda_docs/appletter/2026/210557Orig1s005ltr.pdf
  5. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019. PMID 31599840
  6. White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens 2017. PMID 27977473
  7. Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019. PMID 31599847
  8. Diamond LE, et al. Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. PMID 14963471
  9. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Subcutaneous injection via autoinjector — self-administered by patients as needed before sexual activity (PMIDs: 315998403523016231429064)Subcutaneous injection — used in Phase 1 obesity trials (PMID: 35170192)Nasal (intranasal) formulation — referenced in earlier pre-approval literature in the context of male ED studies (PMID: 17584134); not the approved routeIntravenous route — mentioned as a broader category of peptide administration context for PT-141/bremelanotide review (PMID: 40069591)
Storage
No storage conditions for bremelanotide are described in the reviewed abstracts.
Cautions
Nausea was the most common adverse event in clinical trials (40.0% bremelanotide vs. 1.3% placebo in Phase 3 double-blind studies) and the most common reason for discontinuation.,Focal hyperpigmentation was rare when bremelanotide was dosed per label recommendations but occurred in more than one-third of subjects following up to 16 consecutive daily dosings.,Small but statistically significant transient blood pressure increases were observed; bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment.,Clinically significant drug-drug interactions exist: bremelanotide lowered plasma concentrations of indomethacin and naltrexone.,Adverse event-induced study discontinuation was substantially higher on bremelanotide vs. placebo in re-analyses of Phase 3 data (OR=11.98; NNH: 6).,Sterile technique is essential for subcutaneous self-injection to prevent contamination.

Legal & regulatory status

US FDA

FDA-approved (2019) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (PMIDs: 31429064, 37365323, 23147017, 33455598, 35147466). Also noted as containing a…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification